S. Gettinger

R. Herbst, A. Chiang, D. Zelterman, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Abstract CT077: Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): Clinical characteristics of long-term survivors

David C. Smith, L. Sequist, S. Gettinger, 2017 .

LBA4EVALUATION OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR BRIGATINIB [AP26113] IN PATIENTS (PTS) WITH ALK+ NON–SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES

A. Shaw, S. Gettinger, R. Salgia, 2015 .

An Advanced Practice Nurse Coordinated Multidisciplinary Intervention for Patients with Late-Stage Cancer: A Cluster Randomized Trial.

S. Gettinger, S. Jeon, R. McCorkle, 2015, Journal of palliative medicine.

Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331

S. Gettinger, Han Chang, T. Ciuleanu, 2018, Annals of Oncology.

Immune Checkpoint Inhibitor-Associated Pericarditis.

R. Herbst, D. Rimm, S. Gettinger, 2019, Journal of Thoracic Oncology.

Safety and activity of IPI-504 (retaspimycin hydrochloride) and docetaxel in pretreated patients (pts) with metastatic non-small cell lung cancer (NSCLC).

S. Gettinger, Gregory Riely, G. Weiss, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study.

J. Sosman, F. Hodi, S. Gettinger, 2013 .

First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status

S. Gettinger, F. Shepherd, D. Gerber, 2014 .

Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

David C. Smith, L. Sequist, F. Hodi, 2014 .

A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC).

P. Jänne, H. Wakelee, J. Engelman, 2010 .

Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).

L. Sequist, S. Gettinger, J. Wigginton, 2013 .

Clinical Activity and Safety of Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Advanced Non-Small Cell Lung Cancer (NSCLC)

L. Sequist, S. Gettinger, J. Wigginton, 2012 .

Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

Mark S. Anderson, J. Bluestone, S. Gettinger, 2018, Diabetes.

DIAGNOSIS LUNG Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

M. Socinski, L. Sequist, S. Gettinger, 2013 .

First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP.

M. Socinski, R. Herbst, F. Hirsch, 2018 .

MA16.10 Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening Updates

M. Socinski, R. Herbst, F. Hirsch, 2017 .

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.

Joe Y. Chang, D. Ettinger, L. Chirieac, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952).

L. Schwartz, R. Herbst, F. Hirsch, 2019, Journal of Clinical Oncology.

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC

S. Gettinger, R. Heist, Gregory Riely, 2022, JTO clinical and research reports.

P3.02c-048 A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC: Topic: IT

R. Herbst, A. Chiang, D. Zelterman, 2017 .

Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy

S. Gettinger, M. Sznol, H. Kluger, 2015, Diabetes Care.

Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC).

S. Gettinger, C. Chappey, F. Kabbinavar, 2014 .

Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study.

L. Sequist, R. Herbst, S. Gettinger, 2015 .

Association between anaplastic lymphoma kinase rearrangements (rALK) and the clinical activity of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with non-small cell lung cancer (NSCLC).

L. Sequist, N. Senzer, S. Gettinger, 2010 .

Prospective phase I multi-institutional trial of PD-1 blockade with pembrolizumab during concurrent chemoradiation for locally advanced, unresectable non-small cell lung cancer.

C. Simone, J. Bradley, S. Gettinger, 2019, Journal of Clinical Oncology.

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open‐Label Study of Atezolizumab in PD‐L1–Selected Patients With NSCLC

S. Gettinger, N. Rizvi, J. Chaft, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.

A. Drilon, S. Gettinger, L. Crinò, 2019, The Lancet. Oncology.

PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

S. Gettinger, K. Politi, 2016, Clinical Cancer Research.

Tumor DNA Mutations From Intraparenchymal Brain Metastases Are Detectable in CSF

Abhijit A. Patel, D. Nguyen, S. Gettinger, 2021, JCO precision oncology.

Safety and Response With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Erlotinib in Patients (Pts) With Epidermal Growth Factor Receptor Mutant (EGFR MT) Advanced Non-Small Cell Lung Cancer (NSCLC)

S. Gettinger, N. Rizvi, H. Borghaei, 2014 .

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC).

S. Gettinger, F. Shepherd, D. Gerber, 2014 .

Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC.

S. Gettinger, N. Rizvi, H. Borghaei, 2014 .

Clinical characteristics and outcomes of splenic infarction in cancer patients: a retrospective, single center report of 206 cases

G. Israel, S. Gettinger, J. Bewersdorf, 2021, Journal of Thrombosis and Thrombolysis.

P3.02a-013 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial: Topic: ALK Clinical

Edward S. Kim, H. Groen, T. Clackson, 2017 .

A Phase II trial of pembrolizumab for patients with melanoma or non-small cell lung cancer and untreated brain metastases

Upendra, Chiang, A. Vortmeyer, 2017 .

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

Edward S. Kim, H. Groen, E. Smit, 2022, JTO clinical and research reports.

Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC).

L. Sequist, S. Gettinger, J. Wigginton, 2012 .

Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012.

S. Gettinger, F. Shepherd, D. Gerber, 2017 .

P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets): Track: Immunotherapy.

S. Gettinger, L. Crinò, S. Ramalingam, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

C. Ko, A. Chiang, S. Gettinger, 2016, JAAD case reports.

441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC

C. Rudin, S. Gettinger, R. Heist, 2016 .

First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression.

S. Gettinger, F. Shepherd, D. Gerber, 2015 .

BRIEF REPORT: Immune checkpoint inhibitor associated pericarditis

R. Herbst, D. Rimm, S. Gettinger, 2019 .

SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer

M. Dhodapkar, S. Gettinger, H. Zebroski, 2013, Oncoimmunology.

Brigatinib versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.

Jie Yang, S. Gettinger, M. Ahn, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.

S. Gettinger, M. Bosenberg, N. Rodić, 2016, JAMA dermatology.

Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients.

S. Gettinger, M. Perazella, A. Shirali, 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Immune therapies for lung cancer.

S. Gettinger, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A First-In-Human Dose-Finding Study of the Alk/Egfr Inhibitor AP26113 in Patients with Advanced Malignancies

T. Clackson, A. Shaw, S. Gettinger, 2012 .

Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A.

P. Hegde, I. Wistuba, F. Hirsch, 2015 .

Anti-PD-1 (BMS-936558/MDX-1106/ONO-4538) in Patients With Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers

David C. Smith, J. Taube, F. Hodi, 2012 .

Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)

S. Gettinger, F. Shepherd, D. Gerber, 2014 .

Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.

R. Herbst, A. Chiang, S. Gettinger, 2018 .

Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC).

M. Socinski, S. Gettinger, T. Stinchcombe, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

Edward S. Kim, H. Groen, E. Smit, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer

C. Gridelli, S. Gettinger, M. Ahn, 2018, The New England journal of medicine.

Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo

J. Wolchok, M. Dhodapkar, R. Halaban, 2015, The Journal of Immunology.

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.

William Pao, Gregory J Riely, D Ross Camidge, 2014, Cancer discovery.

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

P. Jänne, S. Gettinger, F. Shepherd, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

S. Gettinger, F. Shepherd, D. Gerber, 2017, The Lancet. Oncology.

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

S. Gettinger, E. Felip, L. Crinò, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

S. Gettinger, F. Shepherd, D. Gerber, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer

P. Jänne, H. Wakelee, J. Engelman, 2017, Cancer Chemotherapy and Pharmacology.

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.

R. Bernards, H. Varmus, M. Ladanyi, 2014, Cancer discovery.

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.

M. Mino‐Kenudson, J. Neal, H. Wakelee, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

S. Gettinger, E. Felip, L. Crinò, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer , 3 rd ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

M. Socinski, L. Sequist, S. Gettinger, 2013 .

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

S. Gettinger, F. Shepherd, D. Gerber, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

N. Schultz, M. Ladanyi, D. Zelterman, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Immune Therapy: What Can We Learn From Acquired Resistance?

S. Gettinger, K. Politi, M. J. Grant, 2021, Lung Cancer.

Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations.

G. Scagliotti, R. Herbst, S. Gettinger, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis

R. Herbst, K. Syrigos, D. Rimm, 2019, Clinical Cancer Research.

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)

R. Herbst, D. Rimm, S. Gettinger, 2019, Journal of Immunotherapy for Cancer.

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

R. Herbst, D. Zelterman, D. Rimm, 2018, Nature Communications.

Scientific Advances in Thoracic Oncology 2016.

H. Groen, C. Rudin, R. Rami-Porta, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

G. Hampton, P. Hegde, I. Wistuba, 2018, Proceedings of the National Academy of Sciences.

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA

Abhijit A. Patel, S. Mane, N. Carriero, 2018, Clinical Cancer Research.

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).

S. Gettinger, M. Hurwitz, P. Hwu, 2020, Cancer discovery.

High SOX2 Levels Predict Better Outcome in Non-Small Cell Lung Carcinomas

Vamsidhar Velcheti, David L. Rimm, Kurt Schalper, 2013, PloS one.

Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma

R. Herbst, S. Gettinger, R. Homer, 2013, Cancer cytopathology.

High Expression of Mammalian Target of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma

G. Bepler, L. Tanoue, D. Boffa, 2009, Clinical Cancer Research.

High Expression of MammalianTarget of Rapamycin Is Associated with Better Outcome for Patients with Early Stage Lung Adenocarcinoma

G. Bepler, D. Boffa, K. Syrigos, 2009 .

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.

David C. Smith, L. Sequist, S. Gettinger, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OA01.04 Tumor Mutation Burden (TMB) by Next Generation Sequencing (NGS) Associates with Survival (OS) in Lung-MAP Immunotherapy Trials S1400I and S1400A

J. Neal, R. Herbst, F. Hirsch, 2021 .

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma

D. Zelterman, S. Gettinger, K. Politi, 2019, Clinical Cancer Research.

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.

A. Iafrate, P. Jänne, L. Sequist, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II Study of Inhaled Doxorubicin Combined with Platinum-Based Therapy for Advanced Non–Small Cell Lung Cancer

S. Gettinger, X. Pan, G. Otterson, 2010, Clinical Cancer Research.

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small cell lung cancer.

F. Hodi, S. Gettinger, T. Mok, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.

Y. Kluger, R. Herbst, A. Chiang, 2020, The Lancet. Oncology.

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

David C. Smith, J. Sosman, L. Sequist, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted therapy in advanced non-small-cell lung cancer.

S. Gettinger, 2008, Seminars in respiratory and critical care medicine.

3094 Nivolumab (NIVO) safety profile: Summary of findings from trials in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC)

S. Gettinger, P. Paik, S. Ramalingam, 2015 .

Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC).

T. Clackson, A. Shaw, S. Gettinger, 2014 .

High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology

L. Tanoue, D. Boffa, K. Syrigos, 2010, BMC Cancer.

Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing.

Torunn I Yock, Nicholas J Carriero, Roy H Decker, 2012, Cancer research.

The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.

Li Shen, John V Heymach, Kevin R Coombes, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy

R. Herbst, D. Rimm, S. Gettinger, 2019, Clinical Cancer Research.

Nivolumab Plus Erlotinib in Patients With EGFR‐Mutant Advanced NSCLC

S. Gettinger, F. Shepherd, D. Gerber, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.

S. Gettinger, F. Shepherd, N. Rizvi, 2014 .

A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non–Small Cell Lung Cancer

S. Gettinger, J. Contessa, R. Decker, 2013, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non – Small Cell Lung Cancer

S. Gettinger, J. Contessa, R. Decker, 2013 .

Immuno-thermal ablations – boosting the anticancer immune response

R. Herbst, S. Gettinger, J. Ludwig, 2017, Journal of Immunotherapy for Cancer.

Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.

S. Gettinger, A. Amini, B. Kavanagh, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types

A. Drilon, J. Subramanian, A. Bardia, 2021, British Journal of Cancer.

A decade of advances in treatment for advanced non-small cell lung cancer.

S. Gettinger, T. Lynch, 2011, Clinics in Chest Medicine.

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Jie Yang, S. Gettinger, M. Ahn, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.

T. Clackson, A. Shaw, S. Gettinger, 2016, The Lancet. Oncology.

A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811).

S. Gettinger, K. Kelly, D. Gandara, 2021, Clinical lung cancer.

Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331.

S. Gettinger, S. Peters, T. Ciuleanu, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403.

R. Herbst, S. Gettinger, K. Kelly, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.

C. Simone, J. Bradley, S. Gettinger, 2020, JAMA oncology.

Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.

Edward S. Kim, H. Groen, E. Smit, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Management of Patients with Advanced Non-Small Cell Lung Cancer

S. Gettinger, H. Deshpande, Laura R. Triano, 2012, Drugs.

Impact of Deferring Radiotherapy in Patients with EGFR-mutant NSCLC That Develop Brain Metastases

S. Gettinger, James B. Yu, W. Magnuson, 2016 .

Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.

H. Groen, W. Pao, E. Smit, 2017, Lung cancer.

Lung Cancer in Older Patients

L. Tanoue, S. Gettinger, 2012 .

HER-1, 2, and 3.

S. Gettinger, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.

David C. Smith, J. Taube, M. Atkins, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oncolytic virus immunotherapy: future prospects for oncology

S. Gettinger, K. Schalper, J. Ludwig, 2018, Journal of Immunotherapy for Cancer.

Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC).

S. Gettinger, R. Heist, S. Ou, 2018 .

Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis.

Nikhil S. Joshi, S. Gettinger, J. Farrell, 2019, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Possible Interaction of Anti–PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases

A. Vortmeyer, A. Chiang, S. Gettinger, 2016, Cancer Immunology Research.

Pityriasis rubra pilaris–like erythroderma in the setting of pembrolizumab therapy responsive to acitretin

S. Gettinger, G. Panse, Emily Coleman, 2018, JAAD case reports.

Treatment of lung cancer in older patients.

L. Tanoue, S. Gettinger, 2007, Clinics in chest medicine.

Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer

S. Gettinger, J. Sosa, H. Deshpande, 2009, Core evidence.

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non – Small-Cell Lung Cancer : Results From the CA 209-003 Study

David C. Smith, Julie, L. Sequist, 2018 .

Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.

G. Giaccone, F. Hodi, S. Gettinger, 2018, European journal of cancer.

Oligometastatic Disease and Local Therapies

S. Gettinger, Navid Hafez, 2020, Cancer journal.

Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial.

David C. Smith, J. Taube, M. Atkins, 2013 .

B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung Cancer: Current Status and Future Direction

R. Herbst, S. Gettinger, 2014, Cancer journal.

A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors.

C. Rudin, A. Jimeno, S. Gettinger, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC

S. Gettinger, L. Crinò, E. Vokes, 2020 .

Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer.

M. Dhodapkar, S. Gettinger, M. Samur, 2020, JCI insight.

Immune Checkpoint Modulation for Non–Small Cell Lung Cancer

Aurélien Marabelle, S. Gettinger, J. Soria, 2015, Clinical Cancer Research.

Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin–bound paclitaxel in patients with advanced solid tumors

L. Harris, D. Zelterman, S. Gettinger, 2015, Cancer.

Quantitative assessment of CMTM6 in the tumor microenvironment and association with response to PD-1 pathway blockade in advanced-stage non-small-cell lung cancer.

R. Herbst, D. Rimm, S. Gettinger, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non–small cell lung cancer (NSCLC): Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status.

Edward S. Kim, H. Groen, E. Smit, 2018 .

Measurement of PD-1, TIM-3 and LAG-3 protein in non-small cell lung carcinomas (NSCLCs) with acquired resistance to PD-1 axis blockers.

R. Herbst, D. Rimm, S. Gettinger, 2017 .

458 First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC)

S. Gettinger, L. Paz-Ares, V. Gontcharova, 2021, Journal for ImmunoTherapy of Cancer.

Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC).

T. Clackson, A. Shaw, S. Gettinger, 2015 .

Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy

S. Gettinger, F. Shepherd, N. Rizvi, 2014 .

Molecular classification of nonsmall cell lung cancer using a 4‐protein quantitative assay

Taxiarchis Botsis, David L Rimm, Dimitrios Dougenis, 2012, Cancer.

Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets).

S. Gettinger, L. Crinò, S. Ramalingam, 2016 .

Brigatinib versus Crizotinib in Anaplastic Lymphoma Kinase (ALK) Inhibitor-Naive Advanced ALK-Positive Non-Small Cell Lung Cancer: Final Results of the Phase 3 ALTA-1L Trial.

S. Gettinger, M. Ahn, E. Felip, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope

S. Gettinger, J. Sosa, H. Deshpande, 2008, Current opinion in oncology.

Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors

L. Schwartz, S. Gettinger, J. Cedarbaum, 2009, Clinical Cancer Research.

MET amplification (amp) as a resistance mechanism to osimertinib.

C. Azzoli, L. Sequist, A. Shaw, 2017 .

Microwave Ablation versus Stereotactic Body Radiotherapy for Stage I Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis.

S. Solomon, R. Suh, S. Gettinger, 2022, Journal of vascular and interventional radiology : JVIR.

A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC).

M. Buyse, S. Gettinger, T. Lynch, 2013 .

Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).

Edward S. Kim, H. Groen, E. Smit, 2016 .

Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer

C. Rudin, S. Gettinger, R. Heist, 2023, ESMO open.

A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations.

C. Schumann, S. Gettinger, Gregory Riely, 2012 .

NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.

J. Larkin, N. Ibrahim, S. Gettinger, 2018 .

First-Line Treatment of Driver-Negative Non-Small Cell Lung Cancer.

S. Gettinger, So Yeon Kim, 2023, Hematology/oncology clinics of North America.

Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer

S. Gettinger, H. Deshpande, Jaclyn C Flanigan, 2010, Biologics : targets & therapy.

Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases.

A. Vortmeyer, R. Herbst, A. Chiang, 2015 .

1229PDSMOKING HISTORY AND RESPONSE TO NIVOLUMAB IN PATIENTS WITH ADVANCED NSCLCS.

C. Sima, S. Gettinger, M. Hellmann, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

1292PALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK+ NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA.

T. Clackson, A. Shaw, S. Gettinger, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis

Xin Zhang, T. Clackson, A. Shaw, 2018, Frontiers in Oncology.

Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers.

S. Gettinger, N. Rizvi, M. Hellmann, 2015, Clinical Lung Cancer.

OA 05.05 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial

Edward S. Kim, Dohoung Kim, S. Gettinger, 2017 .

1344PBrigatinib (BRG) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): Long-term efficacy and safety results from a phase 1/2 trial

A. Shaw, S. Gettinger, R. Camidge, 2017 .

56 Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results

A. Shaw, S. Gettinger, R. Salgia, 2016 .

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

R. Herbst, D. Zelterman, D. Rimm, 2018, Nature Communications.

Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial

S. Gettinger, M. Ahn, R. Camidge, 2019, Annals of Oncology.

Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).

G. Giaccone, F. Hodi, S. Gettinger, 2015 .

Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response.

David C. Smith, J. Taube, M. Atkins, 2012 .

Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)

L. Sequist, A. Chiang, S. Gettinger, 2016 .

Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)

S. Gettinger, N. Rizvi, H. Borghaei, 2014 .

3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses

S. Gettinger, F. Shepherd, D. Gerber, 2015 .

3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC)

S. Gettinger, N. Rizvi, M. Hellmann, 2015 .

OA14.04 Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC

S. Gettinger, L. Crinò, E. Vokes, 2019, Journal of Thoracic Oncology.

OA 17.03 First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update

S. Gettinger, F. Shepherd, D. Gerber, 2017 .

1301PDThree-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)

Burgio, S. Gettinger, L. Crinò, 2017 .

OA03.01 First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012

S. Gettinger, F. Shepherd, D. Gerber, 2017 .

OA03.02 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1–Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study

P. Jänne, S. Gettinger, Melissa L. Johnson, 2017 .

Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer

D. Boffa, A. Chiang, S. Gettinger, 2019, JAMA network open.

Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC).

S. Gettinger, Gregory Riely, B. Solomon, 2013 .

ORAL01.03: CheckMate 012: Safety and Efficacy of First‐Line Nivolumab and Ipilimumab in Advanced NSCLC: Topic: Medical Oncology

S. Gettinger, F. Shepherd, D. Gerber, 2016, Journal of Thoracic Oncology.

sion might already have been achieved. Scrotal ulceration has not recurred with six cycles of ATRA maintenance therapy.

S. Gettinger, N. Scheinfeld, M. Grossbard, 2011 .

ALTA-1L (ALK in lung cancer trial of BrigAtinib in 1st Line): A randomized, phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)–naive, advanced anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC)

S. Gettinger, S. Peters, D. Camidge, 2016 .

OA 14.07 Progress in Lung Squamous Cell Carcinoma from the Lung-MAP Master Protocol (S1400) Sub-Studies S1400A, S1400B, S1400C and S1400D

M. Socinski, J. Engelman, R. Herbst, 2017 .

Updated efficacy and safety results from ALTA, a randomized phase 2 trial of brigatinib in crizotinib-refractory ALK plus NSCLC

S. Gettinger, M. Ahn, D. Camidge, 2018 .

A phase II study of autologous tumor infiltrating lymphocytes (TIL, LN-144/LN-145) in patients with solid tumors.

J. Nieva, S. Gettinger, J. Lutzky, 2019, Journal of Clinical Oncology.

MA15.06 Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC)

R. Herbst, D. Zelterman, D. Rimm, 2017 .

Activity and safety of brigatinib (BRG) in patients (pts) with ALK+ non–small cell lung cancer (NSCLC): Phase (ph) 1/2 trial results.

A. Shaw, S. Gettinger, R. Salgia, 2016 .

Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)‐positive (ALK+) non‐small cell lung cancer (NSCLC) in a phase 1/2 trial: 1330

A. Shaw, S. Gettinger, R. Salgia, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Differential outcomes in patients with uncommon EGFR exon 19 mutations.

D. Zelterman, S. Gettinger, K. Politi, 2018 .

Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers

David C. Smith, J. Taube, F. Hodi, 2012 .

Final Results of a Phase II Prospective Trial Evaluating the Combination of Stereotactic Body Radiotherapy (SBRT) with Concurrent Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)

S. Gettinger, S. Kaech, R. Decker, 2019, International Journal of Radiation Oncology*Biology*Physics.

Impact of Crizotinib Treatment on Patient-Reported Symptoms and Quality of Life (QOL) in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC)

S. Gettinger, R. Salgia, K. Wilner, 2012 .

187TiP Phase II, multicenter study of autologous tumor infiltrating lymphocytes (TIL, LN 144/LN-145/LN-145-S1) in patients with solid tumours

A. Jimeno, S. Gettinger, H. Kluger, 2021, Journal of Thoracic Oncology.

Incorporation of bevacizumab (B) and erlotinib (Er) with induction (Ind) and concurrent (Conc) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC).

M. Socinski, S. Gettinger, T. Stinchcombe, 2008, Journal of Clinical Oncology.

Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

M. Socinski, S. Gettinger, T. Hensing, 2013, Chest.

OA 09.01 Characterizing the Genomic Landscape of EGFR C797S in Lung Cancer Using ctDNA Next-Generation Sequencing

L. Sequist, S. Gettinger, T. Owonikoko, 2017 .

A phase II trial of VNP40101M in patients with relapsed or refractory small cell lung cancer (SCLC) with or without brain metastases

S. Gettinger, T. Mekhail, D. Spigel, 2007 .

A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK-positive (ALK+) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ).

G. Scagliotti, A. Shaw, S. Gettinger, 2012 .

MA15.02 Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC

C. Rudin, S. Gettinger, R. Heist, 2018, Journal of Thoracic Oncology.

Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial.

S. Gettinger, S. Ou, M. Ahn, 2017 .

Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase II ALTA trial

Edward S. Kim, H. Groen, S. Gettinger, 2019, Annals of Oncology.

A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung cancer (NSCLC) stratified by EGFR mutation status.

P. Jänne, L. Sequist, S. Gettinger, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.

R. Bernards, H. Varmus, M. Ladanyi, 2014, Cancer discovery.

Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.

H. Groen, W. Pao, E. Smit, 2014, Cancer discovery.

CheckMate 331: An open-label, randomized phase III trial of nivolumab versus chemotherapy in patients (pts) with relapsed small cell lung cancer (SCLC) after first-line platinum-based chemotherapy (PT-DC).

S. Gettinger, S. Peters, D. Spigel, 2016 .

513 Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study

G. Giaccone, F. Hodi, S. Gettinger, 2015 .

Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial.

S. Gettinger, M. Ahn, D. Camidge, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

1322PBIOMARKERS ASSOCIATED WITH CLINICAL ACTIVITY OF PD-L1 BLOCKADE IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS) IN A PHASE I STUDY OF MPDL3280A.

S. Gettinger, R. Heist, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG).

Shing M. Lee, R. Herbst, S. Gettinger, 2023, JCO clinical cancer informatics.

Immune Checkpoint Inhibitor-Associated Pericarditis.

R. Herbst, D. Rimm, S. Gettinger, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

OA10.04 Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403

S. Gettinger, K. Kelly, D. Gandara, 2018, Journal of Thoracic Oncology.